Ventyx Biosciences announced the appointment of seven additional internationally-recognized scientists and clinicians to its Scientific Advisory Board (SAB) on April 1, 2025. The new members include experts such as Mo Lamkanfi, PhD, Luke O’Neill, PhD, and Ted Dawson, MD, PhD. These additions bring vital discoveries in understanding the role of the NLRP3 inflammasome in neuro- and systemic inflammation.
The expanded SAB also includes specialists at the forefront of clinical development in neurodegenerative and cardiometabolic diseases. This move validates Ventyx’s leadership in the chemistry and biology of the NLRP3 inflammasome. The collective expertise is expected to provide important guidance in both translational and clinical development.
The company is progressing its two potential best-in-class oral NLRP3 inhibitors, VTX3232 and VTX2735, through Phase 2 studies. These studies target Parkinson’s disease, cardiometabolic disease, and recurrent pericarditis. Topline data from the Phase 2 study of VTX3232 in Parkinson’s disease are expected in the second quarter of 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.